Time course of inflammatory cytokines in acute ischemic stroke patients and their relation to inter-alfa trypsin inhibitor heavy chain 4 and outcome

Annals of Indian Academy of Neurology

Volumn 15, Issue 3, 2012, Pages 181-185

  Nayak, Amit R ^a   Kashyap, Rajpal S ^a   Kabra, Dinesh ^a   Purohit, Hemant J ^b   Taori, Girdhar M ^a   Daginawala, Hatim F ^a  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

^b NATIONAL ENVIRONMENTAL ENGINEERING RESEARCH INSTITUTE   (India)

Author keywords

Acute ischemic stroke; cytokine; inter alfa trypsin inhibitor heavy chain 4; prognosis

Indexed keywords

INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN 4; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FOLLOW UP; HEAVY CHAIN; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LACUNAR STROKE; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; STROKE PATIENT;

EID: 84865742697     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.99707     Document Type: Article

References (33)

1. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: New opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999;19:819-34.
2. Chamorro A, Hallenbeck J. The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 2006;37:291-3.
3. Samson Y, Lapergue B, Hosseini H. [Inflammation and ischaemic stroke: Current status and future perspectives]. Rev Neurol (Paris) 2005;161:1177-82.
4. Zhang RL, Chopp M, Li Y, Zaloga C, Jiang N, Jones ML, et al. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 1994;44:1747-51.
5. Matsuo Y, Onodera H, Shiga Y, Shozuhara H, Ninomiya M, Kihara T, et al. Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat. Brain Res 1994;656:344-52.
6. Connolly ES Jr, Winfree CJ, Springer TA, Naka Y, Liao H, Yan SD, et al. Cerebral protection in homozygous nullICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesionin the pathogenesis of stroke. J Clin Invest 1996;97:209-16.
7. Hughes PM, Allegrini PR, Rudin M, Perry VH, Mir AK, Wiessner C. Monocytechemoattractant protein-1 deficiency is protective in a murine stroke model. J Cereb Blood Flow Metab 2002;22:308-17.
8. Chen Y, Hallenbeck JM, Ruetzler C, Bol D, Thomas K, Berman NE, et al. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab 2003;23:748-55.
9. Basic Kes V, Simundic AM, Nikolac N, Topic E, Demarin V. Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem 2008;41:1330-4.
10. Loddick SA, Rothwell NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 1996;16:932-40.
11. Matsumoto T, Ikeda K, Mukaida N, Harada A, Matsumoto Y, Yamashita J, et al. Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8. Lab Invest 1997;77:119-25.
12. Miyakis S, Georgakopoulos P, Kiagia M, Papadopoulou O, Pefanis A, Gonis A, et al. Serial serum procalcitonin changes in the prognosis of acute stroke. Clin Chim Acta 2004;350:237-9.
13. Yip HK, Sun CK, Chang LT, Chen MC, Liou CW. Time course and prognostic value of plasma levels of N-terminal pro-brain natriuretic peptide in patients after ischemic stroke. Circ J 2006;70:447-52.
14. Wunderlich MT, Lins H, Skalej M, Wallesch CW, Goertler M. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 2006;108:558-63.
15. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: An independent prognostic factor. Stroke 2001;32:917-24.
16. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002;33:2459-64.
17. Nayak AR, Kashyap RS, Purohit HJ, Kabra D, Taori GM, Daginawala HF. Evaluation of the inflammatory response in sera from acute ischemic stroke patients by measurement of IL-2 and IL-10. Inflamm Res 2009;58:687-91.
18. Kashyap RS, Kabra DP, Nayak AR, Mishra RN, Deshpande SK, Karandikar P, et al. Protein electrophoretogram in serum of acute ischemic stroke patients and its correlation with S-100BBand neuron specific enolase level: A pilot study. Ann Neurosci 2006;13:36-40.
19. Kashyap RS, Nayak AR, Deshpande PS, Kabra D, Purohit HJ, Taori GM, et al. Inter-alpha-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke. Clin Chim Acta 2009;402:160-3.
20. Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci 2001;22:289-96.
21. Kostulas N, Kivisäkk P, Huang Y, Matusevicius D, Kostulas V, Link H. Ischemic stroke is associated with a systemic increase of blood mononuclear cells expressing interleukin-8 mRNA. Stroke 1998;29:462-6.
22. Kostulas N, Pelidou SH, Kivisäkk P, Kostulas V, Link H. Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 1999;30:2174-9.
23. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-603.
24. Strieter RM, Kunkel SL, Showell HJ, Remick DG, Phan SH, Ward PA, et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science 1989;243:1467-9.
25. Asare K, Gee BE, Stiles JK, Wilson NO, Driss A, Quarshie A, et al. Plasma interleukin-1beta concentration is associated with stroke in sickle cell disease. Cytokine 2010;49:39-44.
26. Frenkel D, Huang Z, Maron R, Koldzic DN, Moskowitz MA, Weiner HL. Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci 2005;233:125-32.
27. Morita Y, Takizawa S, Kamiguchi H, Uesugi T, Kawada H, Takagi S. Administration of hematopoietic cytokines increases the expression of anti-inflammatory cytokine (IL-10) mRNA in the subacute phase after stroke. Neurosci Res 2007;58:356-60.
28. Benveniste EN. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev 1998;9:259-75.
29. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997;15:797-819.
30. Modur V, Li Y, Zimmerman GA, Prescott SM, McIntyre TM. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest 1997;100:2752-6.
31. Benveniste EN, Tang LP, Law RM. Differential regulation of astrocyte TNF-alpha expression by the cytokines TGF-beta, IL-6 and IL-10. Int J Dev Neurosci 1995;13:341-9.
32. Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989;143:3517-23.
33. Al-Bahrani A, Taha S, Shaath H, Bakhiet M. TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr Neurovasc Res 2007;4:31-7.